Regeneron Pharmaceuticals (REGN) Retained Earnings (2009 - 2026)

Regeneron Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $37.6 billion for Q2 2026.

• In Q2 2026, Retained Earnings rose 11.7% year-over-year to $37.6 billion; the TTM figure through Jun 2026 stood at $37.6 billion (up 11.7% YoY), while the FY2025 annual figure was $35.8 billion, up 13.02% from the prior year.
• Retained Earnings for Q2 2026 stood at $37.6 billion, up from $36.4 billion in the prior quarter.
• The five-year high for Retained Earnings was $37.6 billion in Q2 2026, with the low at $19.9 billion in Q1 2022.
• The 5-year median for Retained Earnings is $28.7 billion (2024), against an average of $28.9 billion.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings jumped 66.07% in 2022, then advanced 11.7% in 2026.
• Regeneron Pharmaceuticals' Retained Earnings stood at $23.3 billion in 2022, then gained by 16.96% to $27.3 billion in 2023, then grew by 16.19% to $31.7 billion in 2024, then increased by 13.02% to $35.8 billion in 2025, then advanced by 5.1% to $37.6 billion in 2026.
• Business Quant data shows REGN's Retained Earnings at $37.6 billion in Q2 2026, $36.4 billion in Q1 2026, and $35.8 billion in Q4 2025.